Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Cobimetinib (GDC-0973) is a selective inhibitor of mitogen-activated protein kinase kinase (MEK) (IC50: 0.9 nM). Cobimetinib specifically binds to and inhibits the catalytic activity of MEK1, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation and decreased tumor cell proliferation.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 34.00 | |
2 mg | In stock | $ 47.00 | |
5 mg | In stock | $ 77.00 | |
10 mg | In stock | $ 97.00 | |
25 mg | In stock | $ 183.00 | |
50 mg | In stock | $ 291.00 | |
100 mg | In stock | $ 477.00 | |
500 mg | In stock | Inquiry | |
1 mL * 10 mM (in DMSO) | In stock | $ 90.00 |
Description | Cobimetinib (GDC-0973) is a selective inhibitor of mitogen-activated protein kinase kinase (MEK) (IC50: 0.9 nM). Cobimetinib specifically binds to and inhibits the catalytic activity of MEK1, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation and decreased tumor cell proliferation. |
Targets&IC50 | MEK:0.9 nM |
In vitro | In mice bearing tumors with KRAS and BRAFV600E mutations, Cobimetinib (10 mg/kg, p.o.) has an inhibitory effect on tumor progression. Furthermore, in mice carrying A375 xenografts resistant to treatment, the combined use of Cobimetinib and GDC-0941 further reduces the levels of proteins Hexokinase II, Ksr, c-RAF, and p-MEK. |
In vivo | Cobimetinib exhibits potent inhibitory effects on the growth of various tumor cells, particularly those with KRAS or BRAF mutations. When used in conjunction with GDC-0941, cobimetinib significantly reduces the viability of 888MEL and A2058 cells, inhibits pathways, and increases apoptosis. Additionally, the combination of cobimetinib and vemurafenib markedly intensifies the reduction of GLUT-1 on the cell membranes across all BRAFV600E cell lines. [1] |
Cell Research | Cells are plated in quadruplicate at a density of 3,000 per well in 384-well plates in normal growth medium and allowed to adhere overnight. Compounds are added in 10 concentrations based on a 3-fold dilution series. Cell viability is measured 72 h later using the CellTiter-Glo Luminescent Cell Viability Assay.(Only for Reference) |
Synonyms | RG7420, XL518, GDC-0973 |
Molecular Weight | 531.31 |
Formula | C21H21F3IN3O2 |
CAS No. | 934660-93-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: 44 mg/mL (82.8 mM)
DMSO: 93 mg/mL (175 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Cobimetinib 934660-93-2 Apoptosis MAPK MEK XL 518 RG-7420 GDC0973 Inhibitor inhibit MAP2K MAPKK Mitogen-activated protein kinase kinase XL-518 GDC 0973 RG7420 RG 7420 XL518 GDC-0973 inhibitor